Pharmacological Mechanisms in Alzheimer's Therapeutics

Передняя обложка
A. Claudio Cuello
Springer Science & Business Media, 22 дек. 2007 г. - Всего страниц: 324

Alzheimer’s disease is a serious health concern in developed countries where the population is progressively aging. At the personal level the diagnosis of the disease represents a devastating scenario for both the sufferer and care givers. In recent years medications have been developed that mitigate somewhat the symptoms and delay, for a while, the progression of the disease. It is expected that in the coming years new medications will be developed that are capable of halting the chain of pathological events and symptoms of the disease. This book covers a wide range of the pharmacological mechanism underlying present and potential new therapies. The recent extraordinary advances in our understanding of the cell and molecular biology of Alzheimer’s disease allows for an optimistic forecast of innovative therapies.

This book will be of value to a wide audience interested in cellular and molecular mechanisms leading to the pathology of Alzheimer’s disease and on the multiple, possible, therapeutic opportunities ahead of us. The field of research is enormous and therefore therapeutic targets that have been selected for this volume seem the most hopeful and for which there is a solid rationale. There are a number of emerging therapeutic targets, such as the inactivation/removal of Aß peptides, amongst others, which might have potential applications if specific leading compounds were to be identified.

Результаты поиска по книге

Содержание

OVERVIEW OF THE ALZHEIMERS DISEASE PATHOLOGY
1
TRIAL DESIGNS AND OUTCOMES TO MONITOR NOVEL
28
THE PHARMACOLOGICAL TREATMENT OF ALZHEIMERS
36
A COMPREHENSIVE
50
CHOLINERGIC NEURODEGENERATION IN ALZHEIMERS
64
THE RATIONALE FOR GLUTAMATERGIC THERAPY
105
SECRETASES AS PHARMACOLOGICAL TARGETS
113
gSECRETASE AS A TARGET
125
NONSTEROIDAL ANTIINFLAMMATORY DRUGS NSAIDs
167
THE POTENTIAL APPLICATION OF ANTIOXIDANT
194
A POTENT GENEBASED
212
TAU PATHOLOGY AS A TARGET IN ALZHEIMERS
223
DESIGN OF INHIBITORS OF AMYLOIDb MISFOLDING
238
POTENTIAL APPLICATIONS OF GLYCOSAMINOGLYCAN
255
MULTIFUNCTIONAL NEUROPROTECTIVE DRUGS
274
INTERPRETING CLINICAL STUDIES OF PUTATIVE
296

THE RATIONALE FOR AN IMMUNOLOGICAL
141
NEUROINFLAMMATION ALZHEIMER DISEASE
149

Другие издания - Просмотреть все

Часто встречающиеся слова и выражения

Популярные отрывки

Стр. 188 - Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45-53.
Стр. 92 - Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
Стр. 187 - C. (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl.
Стр. 97 - B. (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type, Science 248, 1124-1126.
Стр. 23 - Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA...
Стр. 136 - Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., JohnsonWood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St.
Стр. 101 - Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.
Стр. 61 - Growdon, JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
Стр. 162 - GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
Стр. 112 - R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Библиографические данные